Samsung Bioepis and Takeda in Biologics Pact

09:14 EDT 23 Aug 2017 | CHEManager

South Korean biopharmaceutical company Samsung Bioepis is taking its first step into novel drug development with an agreement to partner Japan’s Takeda Pharmaceutical. The move expands Samsung Bioepis’ business beyond creating biosimilars, which has been its focus since launching in 2012.

Original Article: Samsung Bioepis and Takeda in Biologics Pact


More From BioPortfolio on "Samsung Bioepis and Takeda in Biologics Pact"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...